SavedAdd your journal

Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 4

The Effect of Intravitreal Ranibizumab Application at Two Different Concentrations on Threshold Retinopathy of Prematurity

İntravitreal Ranibizumab'ın Farklı İki Konsantrasyonda Uygulamasının Eşik Prematüre Retinopatisinde Etkinliği

Damla ACAR ERGİNTÜRK
Mehmet Cüneyt ÖZMEN
ÖZDEMİR ÖZDEMİR
ZÜHAL ÖZEN TUNAY
UĞUR ACAR
Pages
333–336
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

He has been followed up for 9 months and no ocular or systemic side effect was identified.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravitreal anti-vascular endothelial growth factor was decided to perform to a premature boy who was born at 26 weeks gestational age weighing 870 g, upon detection of bilateral zone 2 posterior, stage 2 retinopathy of prematurity (ROP) with plus disease in ophthalmic examination with binocular indirect ophthalmoscopy of him at postconceptual age of 33 weeks.
📊
Key Findings & Data:Intravitreal semi-dose (0.25 mg/0.025 ml) ranibizumab was administered to the right eye of premature infant.
💡
Conclusion & Impact:He has been followed up for 9 months and no ocular or systemic side effect was identified.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intravitreal anti-vascular endothelial growth factor was decided to perform to a premature boy who was born at 26 weeks gestational age weighing 870 g, upon detection of bilateral zone 2 posterior, stage 2 retinopathy of prematurity (ROP) with plus disease in ophthalmic examination with binocular indirect ophthalmoscopy of him at postconceptual age of 33 weeks. Intravitreal semi-dose (0.25 mg/0.025 ml) ranibizumab was administered to the right eye of premature infant. After one day, quarter dose (0.125 mg/0.0125 ml) was administered to the left eye because of incorrect dose adjustment of drug. At third day of treatment, plus disease recovered. However, we performed diod laser photocoagulation bilaterally, because of plus disease and zone 2, stage 3 ROP were determined after 4 weeks of initial intravitreal ranibizumab treatment. At second week of laser treatment, plus disease disappeared again. He has been followed up for 9 months and no ocular or systemic side effect was identified.

Özet

Yirmialtı hafta, 870 gram ağırlığında doğan erkek bebeğin 34. postkonsepsiyonel haftasında indirekt binoküler oftalmoskopi ile yapılan muayenesinde; her iki gözde zon 2 posterior'da evre 2 prematüre retinopatisi (PR) ile birlikte plus hastalık tespit edilmesi üzerine intravitreal antivasküler endotelyal büyüme faktörü uygulamasına karar verildi. Sağ göze yarı doz (0.25 mg/0.025 ml) intravitreal ranibizumab uygulandıktan bir gün sonra sol göze yanlış doz ayarlaması nedeniyle çeyrek dozda (0.125 mg/0.0125 ml) uygulandı.Tedavi sonrası 3. günde her iki gözde de plus hastalığın gerilediği görüldü. Yapılan 4. hafta kontrollerinde her iki gözde plus hastalığın tekrar oluşması ve zone 2 evre 3 PR gelişmesi üzerine her iki göze diod lazer fotokoagülasyon tedavisi uygulandı. Lazer sonrası 2. haftada her iki gözde de plus hastalığın gerilediği gözlendi. Olguda 9 aylık takip süresince herhangi bir oküler veya sistemik yan etki izlenmedi.

🔖

Cite This Article

ERGİNTÜRK, D. A., ÖZMEN, M. C., ÖZDEMİR, Ö., TUNAY, Z. Ö., ACAR, U. (2016). The Effect of Intravitreal Ranibizumab Application at Two Different Concentrations on Threshold Retinopathy of Prematurity. Retina-Vitreus, Cilt: 24 - Sayı: 4, 333–336. https://ajindex.com/articles/304960

References (11)

  1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persis- tent vascular sheath behind each crystalline lens. I.Preliminary report. Am J Ophthalmol 1942;98:203-4. Cryotherapy for Retinopathy of Prematurity Cooperative Group: Mul- ticenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471-79. Early Treatment For Retinopathy Of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: re- sults of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-94.
  2. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008;92:1450-5.
  3. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831-8.
  4. Law JC, Recchia FM, Morrison DG, et al. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 2010;14:6-10.
  5. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravit- real bevacizumab (Avastin) for salvage treatment in progressive thres- hold retinopathy of prematurity. Retina. 2008;28:13-8.
  6. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010;30:24-31.
  7. Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal bevacizumab and lazer in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 2010;248:1257-62.
  8. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity. N Engl J Med 2011;364:603-15.
  9. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovas- cularization in vivo by inhibition of vascular endothelial growth fac- tor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457-61.
  10. Darlow BA, Ells AL, Gilbert CE, et al. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98:170-4.
  11. Karaca C, Oner AO, Mirza E, Polat OA, Sahiner M. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. JAMA Ophthalmol. 2013;131:1099-101 Harder BC, von Baltz S, Jonas JB, et al. Intravitreal low-dosage bevacizumab for retinopathy of prema